WHAT IS CLAIMED IS:

1. A compound of the formula (I):

$$R_{n}$$
 NH_{2}
 N
 R_{2}

5

(I)

wherein

10 R_1 is $-C_{2-6}$ alkyl-NR₃- SO₂ -X-R₄ or $-C_{2-6}$ alkyl-NR₆-SO₂-R₇;

X is a bond or $-NR_5$ -;

R4 is alkyl, aryl, or heteroaryl;

R₂ is selected from the group consisting of:

-hydrogen;

15 -alkyl;

-alkenyl;

-aryl;

-substituted aryl;

-heteroaryl;

20 -substituted heteroaryl;

-alkyl-O-aryl;

- alkyl-O-alkyl;

- alkyl-O- alkenyl; and

- alkyl or alkenyl substituted by one or more substituents selected from the

25 group consisting of:

-OH;

-halogen; $-N(R_3)_2$; $-CO-N(R_3)_2;$ -CO-C₁₋₁₀ alkyl; 5 -CO-O-C1-10 alkyl; $-N_3$; -aryl; -substituted aryl; -heteroaryl; 10 -substituted heteroaryl; -heterocyclyl; -substituted heterocyclyl; -CO-aryl; -CO-(substituted aryl); 15 -CO-heteroaryl; and -CO-(substituted heteroaryl); each \mathbf{R}_3 is independently selected from the group consisting of hydrogen and $C_{1\text{--}10}$ alkyl; \mathbf{R}_5 is selected from the group consisting of hydrogen and $\mathbf{C}_{1\text{-}10}$ alkyl, or \mathbf{R}_4 and \mathbf{R}_5 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; 20 \mathbf{R}_6 is selected from the group consisting of hydrogen and C_{1-10} alkyl; \mathbf{R}_7 is selected from the group consisting of hydrogen and $\mathbf{C}_{1\text{-}10}$ alkyl, or \mathbf{R}_6 and \mathbf{R}_7 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; n is 0 to 4 and each R present is independently selected from the group consisting of $C_{1\text{--}10}$ alkyl, $C_{1\text{--}10}$ alkoxy, halogen and trifluoromethyl, 25 or a pharmaceutically acceptable salt thereof.

- 2. A compound of claim 1 wherein X is a bond.
- 30 3. A compound of claim 2 wherein n is 0.
 - 4. A compound of claim 2 wherein each R₃ is hydrogen.

- 5. A compound of claim 2 wherein R₄ is alkyl
- 6. A compound of claim 2 wherein R₂ is selected from the group consisting of
 5 hydrogen, C₁₋₄ alkyl, and C₁₋₄ alkyl-O- C₁₋₄ alkyl.
 - 7. A compound of claim 2 wherein the dashed bonds are absent.
 - 8. A compound selected from the group consisting of:
- N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide; N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide; N-[4-(4-amino-2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide; N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide; N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide;
- N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide;
 N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide;
 N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide;
 N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]benzenesulfonamide;
 N-[4-(4-amino-2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide;
- N-{8-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]octyl} benzenesulfonamide;
 N-{8-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]octyl} methanesulfonamide;
 N-[8-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)octyl]methanesulfonamide;
- N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-5-(dimethylamino)naphthalene-1-sulfonamide;

 N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-4-methylbenzenesulfonamide;
- yl]propyl}methanesulfonamide;N-[8-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)octyl]benzenesulfonamide;

 $N-\{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-$

```
yl]propyl}benzenesulfonamide;
       N-[4-(4-amino-2-pentyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide;
       N-[4-(4-amino-2-pentyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide;
 5
       N-[8-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)octy] methanesulfonamide:
       N-\{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl\}-4-
       methylbenzenesulfonamide;
       N-[4-(4-amino-2-pentyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-
       yl)butyl]methanesulfonamide;
10
       N-{3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-
       yl]propyl}methanesulfonamide:
       N-\{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2,2-
       dimethylpropyl}methanesulfonamide;
       N-\{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl\}-5-
15
       (dimethylamino)naphthalene-1-sulfonamide;
       N-[3-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide;
       N-\{3-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-
       yl]propyl}methanesulfonamide;
       N-{3-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-
20
       yl]propyl}methanesulfonamide;
       N-\{3-[4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-c]quinolin-1-
       yl]propyl}methanesulfonamide;
       N-{4-[4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-c]quinolin-1-
        yl]butyl}methanesulfonamide;
       N-[4-(4-amino-2-methyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-
25
        yl)butyl]methanesulfonamide hydrochloride;
       N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-4-
       methylbenzenesulfonamide;
        N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]methanesulfonamide;
30
        1-[4-(1,1-dioxidoisothiazolidin-2-yl)butyl]-2-(2-methoxyethyl)-1H-imidazo[4,5-
        c]quinolin-4-amine;
       2-butyl-1-[4-(1,1-dioxidoisothiazolidin-2-yl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
```

 $N-\{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-$

N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide; N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]ethanesulfonamide; 1-(2-amino-2-methylpropyl)- 1H-imidazo[4,5-c]quinoline-4-amine; and

 $N-\{4-[4-amino-2-(cyclopropylmethyl)-1H-imidazo[\overline{4},5-c]$ quinolin-1-yl]butyl}methanesulfonamide; or a pharmaceutically acceptable salt thereof.

20

- 9. A pharmaceutical composition comprising a therapeutically effective amount of a
 10 compound of claim 1 and a pharmaceutically acceptable carrier.
 - 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.
- 15 11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 8 and a pharmaceutically acceptable carrier.
 - 12. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 1 to the animal.
 - 13. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 2 to the animal.
- 14. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 8 to the animal.